Cardio-Oncology Clinic focuses on heart health at Scarborough General for cancer patients - CP24

Take a look through some of the notable data presentations at this year's ESMO Congress. Related to this articleOctober 14th, 2026Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD. Read moreOctober 20th, 2026The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study. Read moreOctober 19th, 2026The agency issued a PDUFA target action date of June 14, 2027. Read moreOctober 19th, 2026Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation. Read moreOctober 19th, 2026Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence. Read moreOctober 16th, 2026Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.

AJMC news storyOncologic factors, not HIV viral suppression status, determine how well people with HIV fare after a lymphoma diagnosis, according to a retrospective cohort study published in HIV Medicine. Lymphoma has remained one of the most common cancers in people with HIV since the earliest years of the epidemic, and that risk has persisted even as antiretroviral therapy (ART) transformed HIV from a fatal illness into a manageable chronic condition. A 2024 protocol published in BMJ Open, outlining a planned systematic review to quantify that excess burden worldwide, noted that people with AIDS face roughly 400 times the risk of high-grade non-Hodgkin lymphoma (NHL) and about 15 times the risk of low-grade NHL compared with the general population. Because ART has sharply reduced AIDS-defining malignancies, clinicians have debated whether virologic control should factor into how aggressively to treat a lymphoma, or whether oncologic staging and histology alone should drive therapy.

Researchers developed a drug for Alzheimer's disease, and then discovered that the molecule already exists in human blood, and is found in lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment. Sergey A. Kozin and colleagues designed a peptide to interfere with the growth of amyloid-β peptide (Aβ) plaques in the brain. Preventing the formation of such plaques has been proposed as a way to prevent Alzheimer's disease or treat it in its earlier stages, in part because Aβ plaque formation is believed to precede and potentially cause the spread of toxic tau protein. Specifically, the authors sought to disrupt abnormal interactions between Aβ and zinc ions, an interaction thought to be key to the plaque formation process.

Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity. IntroductionOvarian cancer is the second most common malignancy of the female genital tract in the United States, according to the American College of Obstetricians and Gynecologists, 2017.1 In terms of mortality, it ranked eighth worldwide in 2013 and fifth in Poland in 2019 among all cancers.2,3 The high mortality rate associated with ovarian cancer is mainly due to its late diagnosis. At the time of diagnosis, two-thirds of patients present with intraperitoneal dissemination, corresponding to International Federation of Gynecology and Obstetrics (FIGO) stage III or IV.4 The most important prognostic indicator in patients with advanced-stage ovarian cancer is the volume of residual disease after cytoreductive surgery.4 The primary treatment approach remains debulking surgery. The goal of this procedure is to achieve complete cytoreduction.